Peptide therapy has exploded in popularity in longevity and performance medicine — but it sits in a regulatory gray zone. Here's what coverage actually looks like in 2026.
Insurance companies cover FDA-approved medications prescribed for specific, covered diagnoses. Most popular peptides — BPC-157, TB-500, Ipamorelin, CJC-1295 — are not FDA-approved and are therefore categorically ineligible for insurance reimbursement. No prior auth process, no appeal pathway, no coverage.
The regulatory landscape tightened further in 2024–2025 when the FDA restricted 503A compounding pharmacies from producing BPC-157 for human use, citing a lack of safety data. This has narrowed the sourcing options for patients who want these peptides.
For a drug to be covered by insurance, it needs three things: an FDA-approved indication, a National Drug Code (NDC), and an ICD-10 diagnosis code that connects the drug to a covered condition. Without FDA approval, none of these exist. A provider cannot even submit a claim — there is no billing code that would result in payment.
The FDA restricted 503A pharmacies from compounding BPC-157 for human use. If you are currently sourcing BPC-157 from a compounding pharmacy, verify that your provider is compliant with current regulations.
Most peptide therapy is self-pay through specialized clinics or telehealth platforms. Pricing varies by peptide and protocol:
Even though insurance won't cover peptides, HSA/FSA funds may be usable if the peptide is prescribed by a licensed physician for a specific medical condition. Always get a prescription and detailed receipt.
No. BPC-157 is not FDA-approved and was restricted from 503A compounding pharmacies in 2024. It is not eligible for insurance coverage.
Semaglutide (Ozempic/Wegovy) and PT-141 (Vyleesi) are FDA-approved and may be covered with prior authorization. Most other peptides are not.